Renal and endocrine effects of fenoldopam and metoclopramide in normal man

A. R.J. Girbes, A. J. Smit, S. Meijer, W. D. Reitsma

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The effects of fenoldopam (FD), a selective dopamine-1 (DA1) agonist in doses from 0.05 to 0.50 μg/kg/min and of the aselective dopamine antagonist metoclopramide (MCP) on blood pressure (BP), sodium excretion and renal hemodynamics were investigated in 10 healthy volunteers. During FD infusion the diastolic BP fell 9 mm Hg with a rise in heart rate. During combined infusion of FD and MCP no changes in BP occurred. Effective renal plasma flow rose for all doses of FD with a maximal increase of 36% and was not influenced by MCP infusion. Glomerular filtration rate remained unchanged. FD induced an increase in sodium and calcium excretion compared to placebo study, which was abolished by MCP. A marked rise of plasma renin activity during FD infusion was noted, blunted by MCP. MCP induced a marked increase of aldosterone, sustained, but blunted, during subsequent FD infusion, suggesting a DA1-mediated influence on aldosterone secretion. During infusion of FD alone, an increased urinary dopamine excretion was observed. We conclude that FD induces: (1) systemic and renal vasodilation and (2) natriuresis by direct stimulation of DA1 receptors in the proximal tubule, which is (partially) counteracted by a rise of plasma renin activity and subsequently of aldosterone.

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalNephron
Volume56
Issue number2
Publication statusPublished - 1 Jan 1990

Cite this

Girbes, A. R. J., Smit, A. J., Meijer, S., & Reitsma, W. D. (1990). Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron, 56(2), 179-185.